Pharmaceutical expert witnesses

Pharmaceutical cases turn on highly technical questions that fall outside the knowledge a layperson — or a generalist attorney — can reasonably evaluate without expert guidance. Whether the dispute involves the adequacy of a drug's labeling, the foreseeability of an adverse reaction, the regulatory history of a new drug application, or the standard of care in post-market pharmacovigilance, the underlying science is dense, the regulatory framework is specific, and the documentary record is voluminous. An expert who can organize and interpret that record — and then communicate it clearly — is not optional in these matters. Courts routinely exclude causation and liability theories that lack qualified expert support. In pharmaceutical litigation specifically, where the defendant will almost always have access to the drug's full development record and internal regulatory communications, retaining an expert who can work from that same body of material is a foundational requirement, not a late-stage enhancement.

The range of experts relevant to pharmaceutical litigation is broader than most attorneys initially anticipate. Clinical pharmacologists address how a drug behaves in the body — absorption, distribution, metabolism, elimination — and are essential in adverse event causation disputes. Toxicologists evaluate dose-response relationships and whether a drug's properties were adequately studied or disclosed. Physicians in the relevant therapeutic area — cardiology, neurology, oncology, and others — opine on how a prescribing clinician would have interpreted label information and whether the drug's risk profile was communicated in a manner consistent with clinical practice. Regulatory affairs specialists address FDA obligations: what the manufacturer was required to submit, report, or disclose, and whether they met those obligations. Biostatisticians are sometimes retained to evaluate the design or interpretation of clinical trials cited in the regulatory record. In cases involving generic drugs, experts familiar with ANDA submissions and bioequivalence standards may also be needed. Complex pharmaceutical matters frequently involve two or three experts with distinct but complementary scopes.

Every expert listed under the pharmaceutical term has passed a baseline verification process before the profile is published. Verification includes confirmation of advanced degree credentials, a review of licensure status in the state of record, a check for publicly available disciplinary actions or sanctions, and a review of the expert's CV for the professional history represented in the profile. For clinical experts, board certification status is confirmed against the relevant certifying body's public records. For regulatory affairs experts, prior employment at pharmaceutical companies or federal agencies is cross-referenced against the professional history disclosed in the CV. The directory does not independently audit every line of an expert's publication history, but peer-reviewed publication claims are spot-checked as part of the intake process. Profiles are reviewed for continued accuracy on a recurring basis, and any expert who does not maintain current credential documentation is removed from active listings until the record is updated.

Once you identify a candidate from the directory, the engagement typically begins with a conflict-of-interest check — the expert will want to confirm they have no prior relationship with any named party, their counsel, or the drug manufacturer. Following clearance, you will ordinarily provide a case summary, the operative pleadings, and a defined document set for initial review. The expert will assess whether the facts support the opinions you need and will advise you on scope before a formal retention agreement is executed. From that point, the engagement moves into record review, followed by report preparation if a written opinion is required by your jurisdiction's rules. Pharmaceutical experts with trial experience understand deposition preparation and are accustomed to the adversarial dynamic of cross-examination on regulatory documents and clinical data. You should discuss prior deposition and trial experience, fee structure, and availability for your specific case schedule at the outset of the retention conversation, as scheduling conflicts are common with experts who are active across multiple engagements.

Pharmaceutical expert opinions are among the most frequently challenged under Daubert and FRE 702, largely because the causation analysis often involves extrapolating from population-level data to individual patient outcomes — a methodological step that courts scrutinize closely. A reliable pharmaceutical causation opinion typically rests on a defined methodology: the expert should be able to articulate the biological mechanism by which the drug is alleged to cause the harm at issue, cite supporting pharmacokinetic or pharmacodynamic data, address the relevant peer-reviewed epidemiological literature, and account for alternative causes through a structured differential analysis. Opinions that rest primarily on case reports, anecdotal clinical experience, or the expert's general reputation in the field are vulnerable to exclusion. Regulatory testimony — addressing what the manufacturer knew or should have known and when — faces a different but related scrutiny: courts will examine whether the expert's standard-of-care opinion reflects the actual regulatory framework that applied to the drug at the relevant time, not a generalized summary of FDA principles. Identifying an expert whose prior testimony has survived Daubert challenge in comparable drug matters is a practical advantage worth investigating during the shortlist phase.

The factual and scientific issues in pharmaceutical cases often look different depending on which side of the caption you represent, and the expert's prior engagement orientation is worth understanding before retention. Plaintiff-side pharmaceutical experts are typically asked to establish that the drug's known or knowable risk profile was inadequately communicated, that the manufacturer's post-market surveillance was deficient, or that the drug caused a specific plaintiff's injury through a defined biological mechanism. Defense-side experts are generally retained to establish that the regulatory record reflects adequate disclosure, that the adverse event was not pharmacologically attributable to the drug at the doses involved, or that alternative causation explains the claimed harm. Some experts have worked both sides of pharmaceutical disputes and are comfortable being cross-examined on that history; others have a consistent posture that may be a strength or a vulnerability depending on your case. The directory's profile summaries include general engagement-side information where the expert has authorized its inclusion, allowing you to make that assessment before initiating contact.